We will be sending out registration information shortly and will offer both in-person and virtual options in light of the continuing impacts of the pandemic.”

Review disclosures made to the Audit Committee by the Company’s CEO and CFO during their certification process for reports on Form 10-K and Form 10-Q about any significant deficiencies in the design or operation of internal controls and procedures or material weaknesses therein and 4 any fraud involving management or other employees who have a significant role in the Company’s internal controls and procedures. 10.

Figure 12: Duration of use BMC Musculoskeletal Disorders 2021 22:186. https://doi.org/10.1186/s12891-021-04054-6 Figure 11: Duration of use Journal of Rehabilitation Medicine, 47 2 (2015): 154-60. https://doi.org/10.2340/16501977-1897 https://doi.org/10.1186/s12891-021-04054-6 https://doi.org/10.2340/16501977-1897 https://www.semanticscholar.org/paper/Hand-grip-fatigability-in-persons-with-multiple-to-Severijns-Lamers/834a2a4e4665c6e9f3d7513507807314d0214828 Ergonomic Grip Design Guide 11 Pre-production validation of the conceptual design is paramount in reducing the overall risk of the program. Common regulations • REACH SVHC, RoHS 3 (EU 2015/863), CA Prop 65, Heavy Metals (CONEG, 94/62/EC) and Conflict Minerals • Substances of Concern (could include phthalates, latex, PVC, BPA, halogens, PAH, flame retardants) Other market-specific regulations • Consumer Product Safety Improvement Act of 2008 (CPSIA) - Lead and phthalate limits for products designed for children • Chemicals of High Concern for Children (CHCC) - Several US states (OR, WA, VT, ME, MN) have lists of chemicals of concern for products . designed for children • Global Automotive Declarable Substance List (GADSL) - Specifically for automotive applications • End of Life Vehicles (ELV) Directive, 2000/53/EC - Restrictions on certain heavy metals for .. automotive applications • EC1223/2009 - Covers prohibited, restricted substances in cosmetic products This list is not exhaustive and regulatory requirements change and evolve.

Seller warrants good and clear title in goods subject to the sale (“Product”) and that the Product conforms at the time of shipment to a Certificate of Analysis, a Certificate of Compliance, or a Product Specification Sheet, if any such document exists, and other specifications signed by Seller (“Specifications”).

Vilken information vi samlar in Begreppet "personlig information" avser all information som, ensam eller i kombination med annan information, direkt eller indirekt identifierar er eller kan förknippas med er, och som ni har givit oss som en del av er registrering och ansökan via denna rekryteringsplattform (dvs. er ansökan och sökandeprofil).

subject= 4 • Un cliente, un fornitore o una terza parte • Pone obiezioni agli impegni contrattuali riguardanti la conformità alle leggi ABAC • Richiede un contratto che limita la concorrenza • Divide un acquisto in un gruppo di acquisti di minore entità, per evitare le approvazioni richieste dal governo o dalla dirigenza Avient • È di proprietà o gestito da un funzionario pubblico o da qualcuno strettamente correlato a un funzionario • Richiede modifiche al prezzo non registrate o pagamenti in contanti • Non è disposto a fornire i dettagli necessari affinché Avient esegua la due diligence • Un fornitore o altra terza parte • Richiede il pagamento a un conto bancario personale o offshore • Non ha esperienza con il prodotto, campo, settore o non dispone di personale qualificato • Pone obiezioni a una dichiarazione di lavoro dettagliata Requisiti di contabilità e tenuta dei registri Ai sensi della maggior parte delle Leggi ABAC, Avient e le sue società affiliate devono mantenere libri e registri accurati e dettagliati e un sistema adeguato di controlli interni.

Registration details will be released shortly.

ASHISH KHANDPUR PRESIDENT & CEO 7 8 PORTFOLIO TRANSFORMATION 8 7% 46% 66% 87% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2015 2020 2023 % o f A dj us te d EB IT D A Commodity JVs Distribution Performance Products & Solutions Specialty Businesses Adjusted EBITDA from Specialty Applications SUSTAINABILITY AS A GROWTH DRIVER 9 LONG-TERM REVENUE GROWTH DRIVERS Sustainable Solutions Composites, Healthcare, Asia / LATAM Overlap Other 60%+ Key Growth Drivers Total Company Revenue Growth Drivers Long-Term Growth Rate Sustainable Solutions 8–12% Composites 8–10% Healthcare 8–10% Asia / LATAM 5% Other 0–2% Avient 6% END MARKET OBSERVATIONS (% OF COMPANY SALES) ENERGY 5% DEFENSE 7% TELECOMMUNICATIONS 4% HEALTHCARE 7% 10 TRANSPORTATION 10% INDUSTRIAL 16% BUILDING & CONSTRUCTION 9% CONSUMER 19% PACKAGING 23% 11 REGIONAL OBSERVATIONS (% OF COMPANY SALES) 11 US & Canada Latin America EMEA Asia 41% 36% 18% 5% Q 4 2023 RE S U LT S Q4 2023 PERFORMANCE VS.

ASHISH KHANDPUR PRESIDENT & CEO 4 5 PORTFOLIO TRANSFORMATION 5 7% 46% 66% 87% 100% 0% 20% 40% 60% 80% 100% 2005 2010 2015 2020 2023 % o f A dj us te d EB IT D A Commodity JVs Distribution Performance Products & Solutions Specialty Businesses Adjusted EBITDA from Specialty Applications SUSTAINABILITY AS A GROWTH DRIVER 7 LONG-TERM REVENUE GROWTH DRIVERS Sustainable Solutions Composites, Healthcare, Asia / LATAM Overlap Other 60%+ Key Growth Drivers Total Company Revenue Growth Drivers Long-Term Growth Rate Sustainable Solutions 8–12% Composites 8–10% Healthcare 8–10% Asia / LATAM 5% Other 0–2% Avient 6% END MARKET OBSERVATIONS (% OF COMPANY SALES) ENERGY 5% DEFENSE 7% TELECOMMUNICATIONS 4% HEALTHCARE 7% 8 TRANSPORTATION 10% INDUSTRIAL 16% BUILDING & CONSTRUCTION 9% CONSUMER 19% PACKAGING 23% 9 REGIONAL OBSERVATIONS (% OF COMPANY SALES) 9 US & Canada Latin America EMEA Asia 41% 36% 18% 5% Q 4 2 0 2 3 R E S U LT S Q4 2023 PERFORMANCE VS.

PRIOR YEAR $790 $710 2022 2023 $107 $112 2022 2023 Sales Adjusted EBITDA (in millions) $0.42 $0.47 2022 PF 2023 Adjusted EPS (in millions) - 10% + 5% + 12% Sales Adjusted EBITDA Adjusted EPS 12 $112 $500 Q4 FY $0.47 $2.30 Q4 FY Q4 AND FULL YEAR 2023 GUIDANCE $710 $3,130 Q4 FY Sales Adjusted EBITDA Adjusted EPS 13 (in millions) (in millions) Guidance: Free Cash Flow $180 $180 Prior Guidance Guidance FREE CASH FLOW & INCREASED DIVIDEND 13th Consecutive Dividend Increase 0.16 0.26 0.42 0.58 0.79 0.85 0.99 1.03 2011 2013 2015 2017 2019 2021 2023 2024 14 S U S TAI NABI L I T Y DAY RE CAP SUSTAINABILITY AS A GROWTH DRIVERLONG-TERM REVENUE GROWTH DRIVERS 60%+ Key Growth Drivers Sustainable Solutions Composites, Healthcare, Asia / LATAM Overlap Other (GDP Growth) Total Company Revenue Growth Drivers Long-Term Growth Rate Sustainable Solutions 8–12% Composites 8–10% Healthcare 8–10% Asia / LATAM 5% Other (GDP growth) 0–2% Avient 6% 17 SUSTAINABILITY TRENDS DRIVE LONG-TERM GROWTH 8-12% Long Term Growth 50 90 2022 2030 Medical Plastics Market Size (in $Billions) 2020 2030 Recycled Plastics Virgin Plastics Growing Demand for Recycled Content Avient Sustainable Solutions 18 46 2023 2032 Global Offshore Annual Wind Installations (in Gigawatts) Sources: McKinsey, Bloomberg, Grand View Research SUSTAINABILITY TRENDS DRIVE LONG-TERM GROWTH 18 • Transformative acquisitions combined with divestitures of more cyclical businesses have improved margins over 400 bps since 2018 • 20% long-term margin goal to be driven by key growth drivers, with sustainable solutions playing a meaningful role 5.4% 11.5% 16.0% 2006 2018 2023E Recovery Growth Drivers Strategic Objective 20%+ +1%+ +3%+ ADJUSTED EBITDA MARGIN EXPANSION 19 • 6% annualized long-term sales growth leveraging sustainable solutions, composites, healthcare, and emerging regions • Expand EBITDA margins to 20% • Deliver annual EBITDA and EPS growth of 10% and 15% • Maintain asset-light, 80% free cash flow conversion profile and be valued as a specialty formulator • Continue fostering our Great Place to Work® culture CREATING A WORLD-CLASS SUSTAINABLE ORGANIZATION 20 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.